<DOC>
	<DOC>NCT01708616</DOC>
	<brief_summary>This single-center, randomized, double-blind, two-period crossover study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic effects of the combination of multiple doses of RO5285119 with a single dose of risperidone in healthy volunteers. Subjects will be randomized to one of 4 treatment sequences of two periods to receive multiple doses of RO5285119 plus a single dose of risperidone or risperidone placebo or multiple doses of RO5285119 placebo plus a single dose of risperidone or risperidone placebo, with a washout period of approximately 3 weeks between treatment periods. Anticipated time on study is up to 12 weeks (from screening through study completion).</brief_summary>
	<brief_title>A Study of the Combination of Multiple Doses of RO5285119 With a Single Dose of Risperidone in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Risperidone</mesh_term>
	<criteria>Healthy male and female adults, 18 50 years of age inclusive Healthy status is defined by absence of evidence of any active or chronic disease following detailed medical and surgical history and a physical examination including vital signs, 12lead ECG, hematology, blood chemistry, serology and urinalysis Body mass index (BMI) 18 to 30 kg/m2 inclusive Women have to be postmenopausal or surgically sterile Male subjects must use a barrier method of contraception for the duration of the study and for 3 months after last dosing Suspicion of regular consumption of drug of abuse, or history of drug or alcohol abuse Positive for hepatitis B, hepatitis C or HIV infection History of clinically significant hypersensitivity or allergic reactions Disorders of the central nervous system, including psychiatric disorders, behavioural disturbances, cerebrovascular events, depression, bipolar disorder, migraine, Parkinson Regular smoker (&gt;5 cigarettes, &gt;3 pipefulls, &gt;3 cigars per day) Administration of an investigational drug or device within 3 months prior to first dosing Hypersensitivity to risperidone or any of its excipients Any other known contraindications to risperidone as stated in the SmPC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>